Sirolimus for arteriovenous malformations

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Jan 2014: Trial registered, NCT02042326
  2. 12 Sep 2014: Trial started, NCT02042326

The trials

NCT02042326: Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations

State
Under way
Phase
Phase 2
People
50 planned
Started
12 Sep 2014
Primary completion
Sep 2027
Arms
Sirolimus treatment
Results
None posted
  1. 22 Jan 2014: Trial registered
  2. 12 Sep 2014: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Fyarro, Hyftor, Rapalimus, Rapamune, Scomara, Sirolimus (SIR).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.